Ophthalmic examinations and SD-OCT performed before and 6 weeks after receiving therapy revealed that HBOT could be used as an adjunct treatment for the management of retinal ischemia and capillary hyperpermeability in DR. Similar results were obtained in a prospective, non-randomized cohort study ...